Video

Faculty Q&A | Portland RT

Posted by
HealthTree Logo HealthTree
• November 21, 2026

Description

In this live faculty Q&A session from the HealthTree Portland Myeloma Roundtable (November 7, 2026), leading myeloma specialists Rebecca Silbermann, MD, MMS, Eva Medvedova, MD, Richa Thakur, MD, Andy Chen, MD, PhD, and Jacqueline Trussell, AGACNP-BC, FNP-BC answer real questions from patients and caregivers.

Key topics discussed in this Q&A:

• Newly diagnosed vs. relapsed/refractory multiple myeloma treatment decisions

• Managing side effects, bone health, infections, and quality of life

• Understanding new drug classes, CAR-T therapy, and overlapping conditions like amyloidosis

Timestamps:

0:00 T-Cell Exhaustion and CAR Persistence

2:47 Prior Transplant and Outcomes

4:20 Disease Control Before CAR T

8:23 Choosing Between CAR T Products

10:22 Non-Secretory Myeloma Monitoring

13:49 Immune Effects and Low Blood Counts

17:17 Treatment-Related Marrow Damage

18:12 Audience Story: Bloodless Transplant

20:40 Marrow Testing and Maintenance

22:44 Using HealthTree and Real-World Data

24:03 Patient Education and Transparency

27:20 Closing Thanks and Housekeeping

Event details: https://healthtree.org/events/portlandrt2026

Transcript

We do have some time for questions and answers again. So here again, he's all again. Say thank you to for being here on a Saturday. We did to Kirti. Kind of a two-pronged question. Number one. Some studies going on now to maintain the vibrancy of the T cells so that we don't see exhaustion. Seems like those are pretty early phase. I'd love to just hear a brief your thoughts about the if that's going to be an effective strategy. And then number two. How long do you expect to see those CARs present in someone's system? And is that prognostic indicative of longer-term success? So persistence of CAR T cells and how well it works. Really depends on that particular CAR T product and that particular CAR T cell and the disease. So in myeloma with CAR, it actually does not really seem to matter that long term persistence of the CAR T cells is necessary for good responses. And that's unlike what we see with some of the lymphoma products, where persistence is critical to have long term remission, particularly like an acute leukemia. So because of that, it's not so critical to try to maintain the, as you were alluding to with your first question, like trying to make sure you still have healthy T cells or, ongoing after, because many times the T cells, the T cells are not needed to stick around long term for CAR to work. Now, whether or not that's going to be the case for other future myeloma CARs, that's to be determined. We do monitor routinely T cell counts after CAR T at our center. We monitor at one month and three months, and then every three months after that until they have recovered to a normal level. We also will monitor your antibody and your B cells to see if they have recovered or not. I was curious for the outcome studies that we saw how many of those are simply had stem cell replacement prior to the other, treatments, such as the bispecific, antibodies. I would suspect that the majority of the IRB that maybe two thirds of the patients would have had prior stem cell transplant. So really, the standard of treatment is still the stem cells. And then the follow up, you're asking someone else to answer. Then middle. In terms of CAR T, you do not have to have a transplant upfront to get CAR T at relapse. And when they've looked at what we call a analysis of patients who had gotten prior transplant or not gone prior to, there's really no difference in outcomes. The best predictor of outcome after CAR T myeloma is what your disease burden coming in with and what is, how healthy and fit you are coming in and how active you are. Those are probably the most important things. It's not whether or not you had a transplant before. It's like how high risk is your myeloma. So if you're standard risk but you still have some, you know, a partial response to the induction, then your outcomes may not be as good with the CAR T as if you have a negative. So I would say I think in general, no matter what cellular therapy go for CAR T or transplant, the better your myeloma is controlled before you go for that therapy, the better your outcomes are going to be. Traditionally, we looked for what we called a very good partial response before transplant, which means you're and spike your free light chains had decreased by about 90% before we would let patients go for transplant. But now, in the era of, like, Dara and all of these new drugs, we try to go for the best response we can even prior to transplant. And it's similar with CAR T. You can take patients with relapse and there's evidence of disease in their blood, in their bone marrow, straight to CAR T without any sort of controlling therapy like bridging or holding therapy. But there are a lot of cases where patients have very bulky disease like plasmacytomas, extramedullary disease outside, or the rate of the myeloma grows so quickly that as an oncologist, I would be worried without putting without giving some sort of controlling therapy right before they go for CAR T. And so those are cases where you'd want to start them. So does that answer your question? It all bit. We routinely take people with active myeloma to CAR T. So but you do not have to be in a, a good remission like you do for stem cell transplant. But as you said, if you have a very high disease burden, your outcomes after CAR T are not very good because you're, you know, that doesn't respond as well. Probably. It's kind of intuitive. There's just too much for it to kill and you're much higher risk for toxicity. So if someone has, you know, like change in the several hundred range or another marker of tumor burden, what we call the LDH or lactate dehydrogenase is very high, or if their marrow is 50% or more, not a good idea. But if you have 20% myeloma in your marrow, that's not an issue. But I wonder if maybe you were asking one of two things, one of which is are we still talking about transplant in general now that we have CAR T? I don't know if that's what you were asking about. Could you repeat the question? I guess I just wasn't quite sure if we've gotten to what your question was, was the question, are we still doing transplant? A lot of the outcomes that were presented. I was just wondering if the studies parse out in the samples, who's had what types of treatment prior to going in, and do those outcomes are they vary by the types of prior treatment that the patient had? Yeah. So they do parse it out. They are consistently parsing out in a CAR T study. If someone has had a treatment that targeted the same target before, if they had a bispecific or a different CAR T before they got that CAR T they will generally say if they had had an anti-CD 38 monoclonal, how many lines of therapy someone will have had. I agree, I think that most of the patients would have had transplant on those trials because of the way myeloma had been treated historically. I am not aware of anything that says that you will do better with CAR T if you had a transplant before. Okay. Another CAR T question. So you've got known large large database and you've got another cell, which looks really cool, but not as many patients on it. Well, as a practitioner, how would you where where do you recommend an as a potential person sitting in the chair. What types of things should we be considering about? Should we go this one or that one? So when one part of it may be taken from you in terms of making a decision, and that it's likely that the new product will only be approved in later lines of treatment and not early on, that's probably because the new one does not have the big randomized study yet to to use it at first or second relapse. So if you're at first or second relapse, it may be a non-issue for you. If you. So it depends on if you're, you know, if you're like the New York Times article that says a third of patients and maybe cured at five years, you know, that's known. And also it also may also go to your health, you know, how or if you're older, you know, you may be at greater risk for the confusion. So that may favor using a product that may have fewer risk of side effect, or you've had other major health issues than maybe you want to go. We have a similar issue in lymphoma, CAR T, where we have some products that are, you know, they may be more active, but they're also higher risk. And so we tend to use them like young healthy patients. And so it may end up being that kind of a discussion. For someone who for someone who is non secreting, would the, the genome predictor, be a helpful guide to a. You know, for future treatment if there's relapse again. We've never heard of the, the genome predictor testing maybe. I think the genome predictor is not the same as what we consider to be relatively real time testing that we get when we're doing blood work to say how much myeloma to get our estimate of how much myeloma is in a person. So it's not going to solve that same kind of problem of, you know, the problem from being a non secretory patient to to being a secret patient. I think it's a similar, conversation that we were having earlier that the genome predictor is looking at a broad in-depth analysis of the myeloma cell characteristics. And that can include information about mutations. It can include information about target expression. But it's not a perfect test. And it takes some time to get the results back. And I don't personally know how those results might change over the course of a person's disease trajectory. A you know, he's, what do they call it? Penta-refractory. So and then you just get to the point of like, are we running out of tools? And that's, you know, so we're just looking for what's what can we use if the disease isn't showing up in, you know, in the, the regular blood markers to, to just guide the next, the next form of treatment. So I guess in general, when you approach myeloma and most of the talks that we talk about, really focus on the free light chains, the bike ride, the immunoglobulins, with patients with non-secretory disease, what really drives what you're looking at are the clinical presentation of symptoms right. So we look at the hemoglobin the kidney function that creatinine the calcium. So that's one marker early that the disease is coming back. But I'll be honest when I have patients in this case I don't want to wait just for those test results. These are patients that I'll usually do annual PET scans. And then like whole body another form of whole body imaging like six months also annually but alternates. There's some sort of imaging every six months in between to track basically what's going on with the myeloma. And then in terms of treatment therapies, whatever you give a patient with secretory disease, you can also give to somebody with non-secretory disease. It's just that you don't have those tools to give you that same like one month feedback. So that's why we have to do this extra testing in between as like type points. I guess we're going to hammer you from both of us with questions. But, a couple things is one of the these questions tie together. So it might be a one answer thing, but with CAR T and bispecifics, it's specific targeted to that cancer cell. But it also is destroying good cells. So the either the language needs to change or it's you know, I don't know if that's part of that thing, but is there a protocol that oncologists would would know that your immune system's going to get hammered by, you know, this, this drug or whatever? And related to that is. It really talk about like the anemic numbers, like the red white cells that are hammered pretty low, which causes fatigue. And we're kind of at this stage of, of disease that we're kind of looking for some therapy to that. And, and if there is anything out there that with trials or, or things to use to help boost like infusions of blood, like red blood or plasma to boost. I don't know what that would be, but are there things that can keep your main system going while you're taking these heavier? Bispecific or CAR T? So in terms of the first part of your two questions, unfortunately for myeloma, there is not really what we call a tumor specific marker, a tumor specific antigen. So things like GPRC5D and BCMA are expressed on plasma cells. So both the good ones as well as the bad myeloma ones. This is unlike the situation, Mike, in some solid tumors where there's actually what we call a tumor specific antigen. And there's actually, you know, cell therapies being developed that will target the tumor specific antigen that's not expressed like there's some some solid cancers that it's not expressed on that normal tissue in that organ, but it is only expressed on the cancer cell. Unfortunately, we have not identified a target like that in myeloma or lymphoma. And then the second part of your question about supportive care and particularly supporting the other blood counts, often someone will have some testing done to confirm why someone has anemia to, to sort out. Is it because of myeloma? Is it because of my myeloma treatment? Or maybe it's because of something else? Maybe someone has an iron deficiency or a vitamin deficiency that can be corrected. Sometimes we do give medications that can help treat anemia by stimulating red blood cells in a different in a different way. And as you mentioned, sometimes we give give transfusions to help when when we don't think the medications are going to be the right choice. No. One thing to note, though, is that's one concern that does come up sometimes, is that has all your prior treatments, all that chemo you had, has that damaged your bone marrow and damage a normal cells? That is a well known complication there, specialized testing that we can do on the bone marrow and sometimes even on the blood, what we call next generation sequencing or things like that, to look for those genetic changes that might say that actually your normal bone marrow has actually been damaged by all your prior treatment. And that's part of the reason why, my blood counts are not recovering very well. And if that has not been done yet, that that would be a reasonable thing to talk about with your physician. I just had a just wanted to make a comment. My daughter was diagnosed at like 35. She had 39%, cancer and a bone marrow. And for years she had anemia. And they would just put her on birth control to control it. But even after her cycle, she still had anemia. In 2016, they called her and said, your proteins are higher. You're pregnant. She's like, no. And they said, well, maybe it's a false positive. So then five years later, she went to a naturopath. And the naturopath said, your proteins are high. That was in 2021. And then in 2022, now 2020 and then 2021, they had double. And so the naturopath said, you need to go to an oncologist. As soon as he read her records said you have multiple myeloma like I was in October. Then she had radiation, chemo. Then she had a stem cell transplant, but she had a bloodless in stem cell transplant at Swedish. And, they always took used the small tubes to take her labs. So to make sure, you know, didn't take her blood count down to low. And she was only in the hospital for two weeks. She she did very well. Three years later, her she had to have the CAR T and she did the bloodless one, and she never went to the hospital. She didn't get the, you know, where you could get that bad thing. I can't remember what it is, but, she did catch the flu while she was going through it, but she's doing well now, and she's at zero, so I'm just very happy about the different. If something happens and you have something else to do. So I'm thankful for all the research. I'm thankful for the doctors that work in this field. Thank you for telling us that. I think there's somebody mentioned there are some tests that see if they're damaged or treatment. Wouldn't that go to a question of how long to continue maintenance if it's your waited? Is there a way to do that to test for that? I think somebody mentioned something about there's some tests that can determine whether cells and or whether the treatment is causing some damage. Is that right? Yeah. So so we can do bone marrow biopsies and look at the other types of young cells that are in the bone marrow to see if there are any abnormalities in how those cells look under the microscope, and then also the genetic material in those cells. Sometimes people can accumulate damage to those cells as a result of treatments. Sometimes people can have abnormalities of those cells that might be independent of prior treatments that they had. I'm not sure that that test would independently say whether someone could stop maintenance or not. But in situations where we think that there is damage to those cells that could have been caused by maintenance, that would certainly be a scenario where we would stop. So it could, would, could go to the judgment question of whether it continue maintenance or not. Would that be examined in each biopsy? Partially so. So in the biopsies, the pathologists do we do more than the MRD. The pathologists look at the sample. They look at the the cells themselves. They comment as if the cells appear normal or if the cells look funny. And if the cells look funny, they'll often call us up and say, hey, these cells looked a little unusual. I would suggest that we look further into this because of these concerns. Thank you. Okay, so, it's so cool being here with our Portland area community. And I see, like, members of the, support group that I belong to through Providence, through IMF and the Seattle groups here and doctors from Portland and Seattle. Lisa just shared about this root of RVD and stem cell and T, and we heard about bispecifics specifically, if we have HealthTree as a platform, like I just uploaded my data today, what do you guys see as how we can leverage HealthTree and like our community with these treatments going like, what could we do now, like with HealthTree or with tools? I mean, we have incredible technology. What do you think we can do with the platform and research? I'm super excited about this app. I was not aware that it existed until I was invited to do this. Speaking engagement with HealthTree. I also downloaded the app while we were here this morning, and I'm excited to kind of get used to it and, and see, how it can benefit our patients. And I'm really excited to share this with my own patients and clinic. What I would like to see is a lot more transparency. Sometimes it's difficult for us. Like I work at OHSU and our computer system doesn't always, it doesn't always upload information from other institutions. And so I'm really looking forward to being able to access some information that I typically would have to spend, you know, a week or so trying to get my support staff to obtain VFX. So I'm really hoping that the HealthTree information will help us receive data faster. The other thing I really liked about the HealthTree app is that you could also, check out the educational videos and even preparing for my own speeches today I was listening to previous, interviews from other myeloma providers throughout the nation, and I was very pleasantly surprised with how well, they they detailed that information and how well they were able to explain things to patients in a way that you guys can understand. I think that's very important. This is a very complicated, cancer to kind of wrap your brain around. Even the lab results are very difficult for people to interpret. And so I really encourage you guys to, you know, take take a look at those videos. There's lots of different videos that explain how myeloma occurs, and lots of symptom management strategies and questions about what does it feel like preparing for an autologous transplant or a bispecific antibody or a CAR T therapy? So, I'm really hoping that you guys can use that information to, to prepare better answers, to ask your own oncology team. I always welcome really educated answers. It helps me know that you guys are paying attention, that we're a team, that you're in this with me. And I find that patients that are educated about their, their myeloma and are asking a lot of questions, those are the patients that are prepared for the next steps. They they they see their symptoms coming on early. They reach out, they ask questions early. That all equates to better outcomes. Thanks. I'd add the HealthTree community, the patient and caregiver community has been so incredibly generous in participation in in clinical trials. The surveys that have been done as part of HealthTree are really remarkable in the reach that they that they have. And we heard a lot about how clinical trials are wonderful. But the pace of progress is unfortunately glacial. And getting real world data. So data about how people in the community are being treated off of studies is really invaluable. And it's a lot of how we learn and how we adjust our treatments for patients on, on a daily basis. Sorry, I have the last question over there. I just want to express the appreciation for all of us and for all of you, and always just you and HealthTree Foundation and everyone involved in this. It was a great forum. And on behalf, I think, of all of us. Right. I want to express our appreciation to all of you. Thank you. All right. I think our time is up. As has been said, we're grateful for you to spend your afternoon with us and help educate and answer and just everything that you do. So thank you so much. Very appreciative. What do I have left for all of you? Look through your packets. Like I mentioned earlier, we'd love to get the feedback forms from you. If you have feedback to give, There's donation envelopes in there if, if you feel so inclined. We are always appreciative of that. And I think that's it. Right? I know you're good. And if anyone is still missing their ballot tickets, come with me. And just again, let's give a round of applause to our faculty. Please.